Pharmacia Corporation today announced that Aromasin® (exemestane tablets) 25 mg once daily received approval from Japan’s Ministry of Health, Labor and Welfare for the treatment of breast cancer in postmenopausal women. Aromasin was studied in postmenopausal women with advanced or recurrent breast cancer that had progressed following anti-estrogen therapy.
“The approval in Japan reinforces the global oncology community’s confidence in Aromasin as an important treatment for breast cancer,” said Gabe Leung, Group Vice President, Global Oncology Franchise. “With the drug now approved in 49 countries, including the world’s top two pharmaceutical markets, Japan and the U.S., Aromasin is an increasing contributor to Pharmacia’s global oncology business.”
First approved in the United Kingdom in 1998, Aromasin was launched in 2000 in the United States, where it is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. Because of its mode of action, Aromasin should not be administered to pre-menopausal women.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!